Loading stock data…
TAK
$16.62-0.06 (-0.36%)
Market ClosedLast close May 1
Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Takeda Pharmaceutical Company Limited in the Healthcare sector is trading at $16.62. The stock is currently 12% below its 52-week high of $18.90, remaining 5.3% above its 200-day moving average. Technical signals show oversold RSI of 24 and bearish MACD signal, explaining why TAK maintains its current momentum and trend strength. The Whystock Score of 75/100 reflects a high-conviction bullish alignment.
Ecosystem Influences
Oversold momentum (RSI 24) — potential for technical mean-reversion
Long-term trend bullish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$16.62
Potential Downside
75.7%
Whystock Fair Value$4.04
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Fundamentals
Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare di...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$52.44B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
75.45
Beta
Defensive asset. Lower volatility than the S&P 500.
0.13
Div Yield
Strong income play. Yield provides a meaningful total return floor.
398.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
1.79%
Volume
Today's trading volume
1.17M
Recent News
Is Takeda Pharmaceutical Company Limited (TAK) One of the Best Japanese Stocks Amid Restructuring Drive?
Takeda Pharmaceutical Company Limited (NYSE:TAK) is one of the best Japanese stocks to buy right now. On April 6, Denali Therapeutics said Takeda Pharmaceutical Company Limited (NYSE:TAK) is ending its collaboration on DNL 593. The two companies were working on developing the investigational therapy for frontotemporal dementia caused by granulin gene mutations. The candidate drug […]
Should Value Investors Buy Takeda Pharmaceutical Co. (TAK) Stock?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
What Makes Denali Therapeutics (DNLI) One of the Best Biotech Stocks to Invest in
Denali Therapeutics Inc. (NASDAQ:DNLI) is one of the 10 best biotech stocks with highest upside potential. On April 6, Denali Therapeutics Inc. (NASDAQ:DNLI) revealed that it has received notice from Takeda (NYSE: TAK) about the termination of the collaboration agreement on developing and commercializing DNL593. This move was due to some strategic reasons and is […]
HUTCHMED Highlights $1.4B Liquidity, 2026 Revenue Outlook, and SAFFRON Catalyst at DB Conference
HUTCHMED (NASDAQ:HCM) executives highlighted 2025 financial results, commercial momentum for its marketed oncology portfolio, and upcoming clinical and regulatory catalysts during a presentation at the 30th Deutsche Bank deposit receipts virtual investor conference. 2025 financial performance and l
Intellia Successfully Edited Genes Inside The Body. Why Shares Aren't Flying.
Intellia Therapeutics could soon win Food and Drug Administration approval for the first-ever drug that edits genes inside a patient's body.